INVIRASE

This brand name is authorized in Austria, Australia, Cyprus, Estonia, Hong Kong, Ireland, Lithuania, Netherlands, Poland, United States

Active ingredients

The drug INVIRASE contains one active pharmaceutical ingredient (API):

1 Saquinavir UNII UHB9Z3841A - SAQUINAVIR MESYLATE

Saquinavir selectively inhibits the HIV protease, thereby preventing the creation of mature infectious virus particles. The HIV protease is an essential viral enzyme required for the specific cleavage of viral gag and gag-pol polyproteins. Read about Saquinavir

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
INVIRASE Film-coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J05AE01	Saquinavir	J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AE Protease inhibitors
Discover more medicines within J05AE01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 10335Y
Country: EE	Ravimiamet	Identifier(s): 1199516, 1199527
Country: HK	Department of Health Drug Office	Identifier(s): 42535, 54309
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1010803, 1028765
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 78603
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100138155, 100311100
Country: US	FDA, National Drug Code	Identifier(s): 0004-0244